International Isotopes Inc
INIS
$0.04−10.75%
At close · Nov 17, 2026
Mkt cap
$37.04M
EV/Sales
2.86
P/E ratio
—
FY2025 Revenue
$13.07M
EPS (FY2025)
—
Gross Margin (FY2025)
58.93%
Profit Margin (FY2025)
−6.95%
Beta
1.17
Div yield
—
Sector
Healthcare
What matters now, from SEC filings and analyst ratings
Takeaway
A takeaway appears here once the latest filing has been analyzed.
Analysts
Sector-relative grades for valuation, growth, profitability, momentum and revisions
Form 4 trades, last 90 days
No open-market insider buy or sell of INIS since Aug 20, 2026.
Latest SEC filings
Source: SEC EDGAR · Latest filing Oct 1, 2026
Latest stored headlines
International Isotopes Inc (INIS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported INIS revenue for 2025-12-31 was $13.1M. Net income was -$908.0K. Revenue was down 6.0% from 2024-12-31 to 2025-12-31. INIS currently screens at market cap $37.0M.
Use this INIS research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full INIS income, balance, and cash tables.
† Total Debt: Derived: short-term debt plus long-term debt (no total debt stored).
International Isotopes Inc (INIS) is a drug manufacturers - specialty & generic company in the Healthcare sector.
Latest cached International Isotopes Inc (INIS) revenue for Dec 31, 2025 was $13.1M. Net income was -$908.0K. Statements: https://lician.com/financials/inis
International Isotopes Inc (INIS) market capitalization is $37.0M on the latest cached snapshot.
International Isotopes Inc (INIS) cached previous close $0.04; day range $0.04 – $0.04; volume 80,255.
The latest cached INIS filing is 8-K · Oct 1, 2026. Filings: https://lician.com/sec/inis
SEC filings · latest fiscal year FY2025
Free shows the newest 2 years. FY2022–FY2023 on Pro
−6.0%
Revenue growth year over year
Institutional holders from SEC 13F filings
10-Q results and the earnings calendar
Revenue and EPS are GAAP diluted from the 10-Q. Beat or miss compares the calendar's actual with its estimate on the same basis (adj.), or revenue with the revenue estimate.
Quant rating
MetricsHow it works—Not rated: market cap below $100M. Factor grades are still shown.
Lician Quant Grades · vs 573 Healthcare stocks · Nov 18, 2026
Next earnings
—
No upcoming report date on file.
Short interest
0.01%of today’s float
1.0 days to cover
+100.1% vs prior report
FINRA · settled Oct 30Short data
52-week range
$0.04$0.10
Price $0.04 · 64.3% below high
Low $0.04, high $0.10, last $0.04.Daily closesChart